Works matching AU Leavitt, Blair R.

Results: 89
    1

    Cell-specific mechanisms drive connectivity across the time course of Huntington's disease.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-025-60556-0
    By:
    • Estevez-Fraga, Carlos;
    • Sebenius, Isaac;
    • Hansen, Justine Y.;
    • Hänisch, Benjamin;
    • Zeun, Paul;
    • Scahill, Rachael I.;
    • Gregory, Sarah;
    • Johnson, Eilanoir B.;
    • Wild, Edward J.;
    • Byrne, Lauren M.;
    • Durr, Alexandra;
    • Landwehrmeyer, Bernhard;
    • Leavitt, Blair R.;
    • Misic, Bratislav;
    • Valk, Sofie Louise;
    • Rees, Geraint;
    • Tabrizi, Sarah J.;
    • McColgan, Peter
    Publication type:
    Article
    2
    3
    4
    5
    6

    A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers.

    Published in:
    Movement Disorders, 2015, v. 30, n. 3, p. 393, doi. 10.1002/mds.26118
    By:
    • Sturrock, Aaron;
    • Laule, Corree;
    • Wyper, Katy;
    • Milner, Ruth A.;
    • Decolongon, Joji;
    • Santos, Rachelle Dar;
    • Coleman, Allison J.;
    • Carter, Kimberley;
    • Creighton, Susan;
    • Bechtel, Natalie;
    • Bohlen, Stefan;
    • Reilmann, Ralf;
    • Johnson, Hans J.;
    • Hayden, Michael R.;
    • Tabrizi, Sarah J.;
    • Mackay, Alex L.;
    • Leavitt, Blair R.
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15

    Association of CAG Repeats With Long-term Progression in Huntington Disease.

    Published in:
    JAMA Neurology, 2019, v. 76, n. 11, p. 1375, doi. 10.1001/jamaneurol.2019.2368
    By:
    • Langbehn, Douglas R.;
    • Stout, Julie C.;
    • Gregory, Sarah;
    • Mills, James A.;
    • Durr, Alexandra;
    • Leavitt, Blair R.;
    • Roos, Raymund A. C.;
    • Long, Jeffrey D.;
    • Owen, Gail;
    • Johnson, Hans J.;
    • Borowsky, Beth;
    • Craufurd, David;
    • Reilmann, Ralf;
    • Landwehrmeyer, G. Bernhard;
    • Scahill, Rachael I.;
    • Tabrizi, Sarah J.
    Publication type:
    Article
    16

    Survival End Points for Huntington Disease Trials Prior to a Motor Diagnosis.

    Published in:
    JAMA Neurology, 2017, v. 74, n. 11, p. 1352, doi. 10.1001/jamaneurol.2017.2107
    By:
    • Long, Jeffrey D.;
    • Mills, James A.;
    • Leavitt, Blair R.;
    • Durr, Alexandra;
    • Roos, Raymund A.;
    • Stout, Julie C.;
    • Reilmann, Ralf;
    • Landwehrmeyer, Bernhard;
    • Gregory, Sarah;
    • Scahill, Rachael I.;
    • Langbehn, Douglas R.;
    • Tabrizi, Sarah J.
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23

    Untargeted metabolomics and infrared ion spectroscopy identify biomarkers for pyridoxine-dependent epilepsy.

    Published in:
    2021
    By:
    • Engelke, Udo F. H.;
    • van Outersterp, Rianne E.;
    • Merx, Jona;
    • van Geenen, Fred A. M. G.;
    • van Rooij, Arno;
    • Berden, Giel;
    • Huigen, Marleen C. D. G.;
    • Kluijtmans, Leo A. J.;
    • Peters, Tessa M. A.;
    • Al-Shekaili, Hilal H.;
    • Leavitt, Blair R.;
    • de Vrieze, Erik;
    • Broekman, Sanne;
    • van Wijk, Erwin;
    • Tseng, Laura A.;
    • Kulkarni, Purva;
    • Rutjes, Floris P. J. T.;
    • Mecinović, Jasmin;
    • Struys, Eduard A.;
    • Jansen, Laura A.
    Publication type:
    journal article
    24
    25
    26

    A novel mouse model for pyridoxine-dependent epilepsy due to antiquitin deficiency.

    Published in:
    Human Molecular Genetics, 2020, v. 29, n. 19, p. 3266, doi. 10.1093/hmg/ddaa202
    By:
    • Al-Shekaili, Hilal H.;
    • Petkau, Terri L.;
    • Pena, Izabella;
    • Lengyell, Tess C.;
    • Verhoeven-Duif, Nanda M.;
    • Ciapaite, Jolita;
    • Bosma, Marjolein;
    • van Faassen, Martijn;
    • Kema, Ido P.;
    • Horvath, Gabriella;
    • Ross, Colin;
    • Simpson, Elizabeth M.;
    • Friedman, Jan M.;
    • van Karnebeek, Clara;
    • Leavitt, Blair R.
    Publication type:
    Article
    27
    28
    29

    Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.

    Published in:
    Human Molecular Genetics, 2007, v. 16, n. 15, p. 1845, doi. 10.1093/hmg/ddm133
    By:
    • Kuhn, Alexandre;
    • Goldstein, Darlene R.;
    • Hodges, Angela;
    • Strand, Andrew D.;
    • Sengstag, Thierry;
    • Kooperberg, Charles;
    • Becanovic, Kristina;
    • Pouladi, Mahmoud A.;
    • Sathasivam, Kirupa;
    • Cha, Jang-Ho J.;
    • Hannan, Anthony J.;
    • Hayden, Michael R.;
    • Leavitt, Blair R.;
    • Dunnett, Stephen B.;
    • Ferrante, Robert J.;
    • Albin, Roger;
    • Shelbourne, Peggy;
    • Delorenzi, Mauro;
    • Augood, Sarah J.;
    • Faull, Richard L.M.
    Publication type:
    Article
    30
    31
    32
    33

    Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.

    Published in:
    Human Molecular Genetics, 2003, v. 12, n. 13, p. 1555, doi. 10.1093/hmg/ddg169
    By:
    • Slow, Elizabeth J.;
    • van Raamsdonk, Jeremy;
    • Rogers, Daniel;
    • Coleman, Sarah H.;
    • Graham, Rona K.;
    • Deng, Yu;
    • Oh, Rosemary;
    • Bissada, Nagat;
    • Hossain, Sazzad M.;
    • Yang, Yu-Zhou;
    • Li, Xiao-Jiang;
    • Simpson, Elizabeth M.;
    • Gutekunst, Claire-Anne;
    • Leavitt, Blair R.;
    • Hayden, Michael R.
    Publication type:
    Article
    34

    HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis.

    Published in:
    Human Molecular Genetics, 2002, v. 11, n. 23, p. 2815, doi. 10.1093/hmg/11.23.2815
    By:
    • Singaraja, Roshni R.;
    • Hadano, Shinji;
    • Metzler, Martina;
    • Givan, Scott;
    • Wellington, Cheryl L.;
    • Warby, Simon;
    • Yanai, Anat;
    • Gutekunst, Claire-Anne;
    • Leavitt, Blair R.;
    • Yi, Hong;
    • Fichter, Keith;
    • Gan, Lu;
    • McCutcheon, Krista;
    • Chopra, Vikramjit;
    • Michel, Jennifer;
    • Hersch, Steven M.;
    • Ikeda, Joh-E;
    • Hayden, Michael R.
    Publication type:
    Article
    35

    Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.

    Published in:
    Human Molecular Genetics, 2002, v. 11, n. 17, p. 1939, doi. 10.1093/hmg/11.17.1939
    By:
    • Chan, Edmond Y.W.;
    • Luthi-Carter, Ruth;
    • Strand, Andrew;
    • Solano, Steven M.;
    • Hanson, Sarah A.;
    • DeJohn, Molly M.;
    • Kooperberg, Charles;
    • Chase, Kathryn O.;
    • DiFiglia, Marian;
    • Young, Anne B.;
    • Leavitt, Blair R.;
    • Cha, Jang-Ho J.;
    • Aronin, Neil;
    • Hayden, Michael R.;
    • Olson, James M.
    Publication type:
    Article
    36
    37
    38

    Differential Susceptibility to Excitotoxic Stress in YAC128 Mouse Models of Huntington Disease between Initiation and Progression of Disease.

    Published in:
    Journal of Neuroscience, 2009, v. 29, n. 7, p. 2193, doi. 10.1523/JNEUROSCI.5473-08.2009
    By:
    • Graham, Rona K.;
    • Pouladi, Mahmoud A.;
    • Joshi, Prasad;
    • Ge Lu;
    • Yu Deng;
    • Nan-Ping Wu;
    • Figueroa, Bryan E.;
    • Metzler, Martina;
    • André, Véronique M.;
    • Slow, Elizabeth J.;
    • Raymond, Lynn;
    • Friedlander, Robert;
    • Levine, Michael S.;
    • Leavitt, Blair R.;
    • Hayden, Michael R.
    Publication type:
    Article
    39
    40
    41

    Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease.

    Published in:
    Human Brain Mapping, 2016, v. 37, n. 12, p. 4615, doi. 10.1002/hbm.23332
    By:
    • Orth, Michael;
    • Gregory, Sarah;
    • Scahill, Rachael I;
    • Mayer, Isabella SM;
    • Minkova, Lora;
    • Klöppel, Stefan;
    • Seunarine, Kiran K;
    • Boyd, Lara;
    • Borowsky, Beth;
    • Reilmann, Ralf;
    • Bernhard Landwehrmeyer, G.;
    • Leavitt, Blair R;
    • Roos, Raymund AC;
    • Durr, Alexandra;
    • Rees, Geraint;
    • Rothwell, John C;
    • Langbehn, Douglas;
    • Tabrizi, Sarah J
    Publication type:
    Article
    42
    43

    Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.

    Published in:
    Human Brain Mapping, 2013, v. 34, n. 3, p. 519, doi. 10.1002/hbm.21449
    By:
    • Scahill, Rachael I.;
    • Hobbs, Nicola Z.;
    • Say, Miranda J.;
    • Bechtel, Natalie;
    • Henley, Susie M.D.;
    • Hyare, Harpreet;
    • Langbehn, Douglas R.;
    • Jones, Rebecca;
    • Leavitt, Blair R.;
    • Roos, Raymund A.C.;
    • Durr, Alexandra;
    • Johnson, Hans;
    • Lehéricy, Stéphane;
    • Craufurd, David;
    • Kennard, Christopher;
    • Hicks, Stephen L.;
    • Stout, Julie C.;
    • Reilmann, Ralf;
    • Tabrizi, Sarah J.
    Publication type:
    Article
    44
    45

    Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery.

    Published in:
    Journal of Neurochemistry, 2015, v. 135, n. 5, p. 1019, doi. 10.1111/jnc.13378
    By:
    • Wagner, Leona;
    • Wolf, Raik;
    • Zeitschel, Ulrike;
    • Rossner, Steffen;
    • Petersén, Åsa;
    • Leavitt, Blair R.;
    • Kästner, Florian;
    • Rothermundt, Matthias;
    • Gärtner, Ulf‐Torsten;
    • Gündel, Daniel;
    • Schlenzig, Dagmar;
    • Frerker, Nadine;
    • Schade, Jutta;
    • Manhart, Susanne;
    • Rahfeld, Jens‐Ulrich;
    • Demuth, Hans‐Ulrich;
    • Hörsten, Stephan
    Publication type:
    Article
    46

    Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease: Evaluation of Deutetrabenazine Dosages (> 48 mg/d versus ≤ 48 mg/d) for Chorea in Huntington Disease: S. Frank et al

    Published in:
    CNS Drugs, 2025, v. 39, n. 2, p. 185, doi. 10.1007/s40263-024-01139-3
    By:
    • Frank, Samuel;
    • Testa, Claudia M.;
    • Goldstein, Jody;
    • Kayson, Elise;
    • Leavitt, Blair R.;
    • Oakes, David;
    • O'Neill, Christine;
    • Whaley, Jacquelyn;
    • Gross, Nicholas;
    • Chaijale, Nayla;
    • Barash, Steve;
    • Gordon, Mark Forrest
    Publication type:
    Article
    47

    The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.

    Published in:
    CNS Drugs, 2022, v. 36, n. 11, p. 1207, doi. 10.1007/s40263-022-00956-8
    By:
    • Frank, Samuel;
    • Testa, Claudia;
    • Edmondson, Mary C.;
    • Goldstein, Jody;
    • Kayson, Elise;
    • Leavitt, Blair R.;
    • Oakes, David;
    • O'Neill, Christine;
    • Vaughan, Christina;
    • Whaley, Jacquelyn;
    • Gross, Nicholas;
    • Gordon, Mark Forrest;
    • Savola, Juha-Matti;
    • The Huntington Study Group/ARC-HD Investigators and Coordinators;
    • Stamler, David;
    • Bockus, Margaret;
    • Leyva, Stephanie;
    • Snively, Victoria;
    • Wong, Cynthia;
    • Mallonee, William M.
    Publication type:
    Article
    48
    49

    Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease.

    Published in:
    Journal of the International Neuropsychological Society, 2016, v. 22, n. 6, p. 595, doi. 10.1017/S1355617716000321
    By:
    • Labuschagne, Izelle;
    • Cassidy, Amy Mulick;
    • Scahill, Rachael I.;
    • Johnson, Eileanoir B.;
    • Rees, Elin;
    • O'Regan, Alison;
    • Queller, Sarah;
    • Frost, Chris;
    • Leavitt, Blair R.;
    • Dürr, Alexandra;
    • Roos, Raymond;
    • Owen, Gail;
    • Borowsky, Beth;
    • Tabrizi, Sarah J.;
    • Stout, Julie C.
    Publication type:
    Article
    50